The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Bayer AGEU/1/08/472/1-8

Main Information

Trade NameXarelto
Active SubstancesRivaroxaban
Dosage FormFilm-coated tablet
Licence HolderBayer AG
Licence NumberEU/1/08/472/1-8

Group Information

ATC CodeB01AF Direct factor Xa inhibitors
B01AF01 rivaroxaban


Licence Issued30/09/2008
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - HCP

Educational Materials - Patient

« Back